This brand name is authorized in Germany
The drug LENOXIN contains one active pharmaceutical ingredient (API):
|
1
Digoxin
UNII 73K4184T59 - DIGOXIN
|
|
Digoxin increases contractility of the myocardium by direct activity. The primary action of digoxin is specifically to inhibit adenosine triphosphatase, and thus sodium-potassium (Na+ - K+) exchange activity, the altered ionic distribution across the membrane resulting in an augmented calcium ion influx and thus an increase in the availability of calcium at the time of excitation-contraction coupling. The potency of digoxin may therefore appear considerably enhanced when the extracellular potassium concentration is low, with hyperkalaemia having the opposite effect. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C01AA05 | Digoxin | C Cardiovascular system → C01 Cardiac therapy → C01A Cardiac glycosides → C01AA Digitalis glycosides |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: DE | Bundesinstitut fĂźr Arzneimittel und Medizinprodukte | Identifier(s): 01996390, 02158372 |
Š All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
